NEW YORK, Jan. 11 --
Curemark (http://www.curemark.com/), a drug research and development company that focuses on the treatment of neurological diseases, has retained Rubenstein Public Relations (http://www.rubensteinpr.com/) to help raise national, regional, and industry awareness of the organization's research, treatments and founder, Dr. Joan Fallon. Curemark is developing an autism treatment that will be one of the first to address the underlying physiology of autism.
The company's initial products are based upon breakthrough observations by Dr. Joan Fallon, which revealed a lack of protein digestion caused by enzyme deficiencies in children with autism and ADHD, affecting the production of key chemicals needed for brain function. The company is currently conducting Phase III clinical trials for its autism treatment, CM-AT.
Richard Rubenstein, president of Rubenstein Public Relations, said: "We are focusing on increasing Curemark's visibility to ensure that pharmaceutical industry influencers and consumers are aware of Dr. Fallon and her team's unprecedented achievements. Dr. Fallon is an incredible visionary and we are delighted to work with a company that has the potential to materially affect the lives of children and young adults who are suffering from debilitating diseases."
Dr. Joan Fallon, founder and CEO of Curemark, said: "Curemark has an incredible team whose groundbreaking efforts recently led to a landmark finding that demonstrated protein digestion deficiencies in a subset of children with autism. We look forward to partnering with the agency as we continue our cutting-edge studies and clinical trials."
Based in Rye, New York, Curemark focuses on the treatment of neurological diseases by addressing certain key gastrointestinal/pancreatic secretory deficiencies. To learn more about Curemark's innovative science, visit www.curemark.com.
SOURCE Rubenstein Public Relations
Advertisement
The company's initial products are based upon breakthrough observations by Dr. Joan Fallon, which revealed a lack of protein digestion caused by enzyme deficiencies in children with autism and ADHD, affecting the production of key chemicals needed for brain function. The company is currently conducting Phase III clinical trials for its autism treatment, CM-AT.
Advertisement
Richard Rubenstein, president of Rubenstein Public Relations, said: "We are focusing on increasing Curemark's visibility to ensure that pharmaceutical industry influencers and consumers are aware of Dr. Fallon and her team's unprecedented achievements. Dr. Fallon is an incredible visionary and we are delighted to work with a company that has the potential to materially affect the lives of children and young adults who are suffering from debilitating diseases."
Dr. Joan Fallon, founder and CEO of Curemark, said: "Curemark has an incredible team whose groundbreaking efforts recently led to a landmark finding that demonstrated protein digestion deficiencies in a subset of children with autism. We look forward to partnering with the agency as we continue our cutting-edge studies and clinical trials."
Based in Rye, New York, Curemark focuses on the treatment of neurological diseases by addressing certain key gastrointestinal/pancreatic secretory deficiencies. To learn more about Curemark's innovative science, visit www.curemark.com.
SOURCE Rubenstein Public Relations
